A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. [electronic resource]
Producer: 20080904Description: 53-61 p. digitalISSN:- 1874-1754
- Abciximab
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Cost Control
- Cost-Benefit Analysis
- Drug-Eluting Stents -- economics
- Female
- Hospital Costs
- Humans
- Immunoglobulin Fab Fragments -- administration & dosage
- Immunosuppressive Agents -- administration & dosage
- Infusions, Intravenous
- Male
- Middle Aged
- Myocardial Infarction -- mortality
- Platelet Aggregation Inhibitors -- administration & dosage
- Prospective Studies
- Sirolimus -- administration & dosage
- Statistics, Nonparametric
- Stents -- economics
- Tirofiban
- Treatment Outcome
- Tyrosine -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.